Jerome and Nancy Kohlberg Professor of Medicine
Dana-Farber Cancer Institute
Dana Farber Cancer Institute
44 Binney St
Boston MA 02115
AACR/ASCO Workshop on Methods in Clinical Cancer Research
2006 - 2007
Research Program Committee (RPC) Award Program
TAP CaPSURE™ Scholarship
ASCO Foundation MERIT Award
ASCO-PROSTATE foundation MERIT Award
Korea Urological Cancer Society Recognition Award
The George P. Canellos Award for Excellence in Clinical Investigation and Patient Care
Eugene P. Schonfeld Award
2018 - 2022
Highly Cited Researcher, Clinical Medicine (Top 1%)
Giant of Cancer Care, Genitourinary Cancer
Lifetime Achievement Award in Global Oncology
I lead the Genitourinary (GU) Medical Oncology Division at Dana-Farber Cancer Institute and I am a clinician and translational scientist specialized in the management of renal cell carcinoma (RCC). My clinical expertise in this area guides my translational research, which involves understanding RCC tumor biology (including genetics and the tumor microenvironment) and investigating tissue- and blood-based biomarkers. My laboratory initially focused on interrogating genomic alterations as biomarkers for anti-angiogenic drug efficacy in advanced RCC. Using multi-OMICS approaches, our focus has expanded to deciphering mechanisms of response and resistance to systemic therapy, including immune checkpoint inhibitors (ICIs) and novel agents. We also are designing biomarker-based clinical trials to provide rationale systemic therapies in patients with renal cancers. I have contributed to the understanding of the underlying biology and rationale for therapies in rare RCC variants such as papillary and sarcomatoid renal cancers, in addition to my contributions to the three The Cancer Genome Atlas (TCGA) working groups dedicated to kidney cancer. Finally, I have conceived, planned, and led several randomized clinical trials in metastatic and adjuvant RCC that lead to multiple FDA approvals. In any research project, I seek to assemble a team of scientists, clinicians, and statisticians at various career stages and from multiple disciplines, and emphasize critical thinking, teamwork, and mentorship to achieve our aims.
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
to make corrections and additions.
Jul 1, 2022 - Jun 30, 2027
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
Jan 10, 2020 - Jun 30, 2022
Tissue-based predictive biomarkers for Cabozantinib therapy in metastatic renal cell carcinoma
(BRASTIANOS, PRISCILLA KALIOPI)
Sep 1, 2018 - Aug 31, 2021
Identification of genomic drivers of brain metastases in renal cell carcinoma
Jul 9, 2015 - Jun 30, 2017
Genetic Predictors of Response to mTOR inhibitors in advanced Renal Cancer
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.